Bookmarks

ISARIC 4C
Datasets (1)
ISARIC4C COVID-19 Clinical Information Network (CO-CIN)
Dataset population size: 270,230
Health and disease
Collections (1)
Analysis Scripts & Software (0)
Data Uses (27)
Presentation, management and outcome of patients with COVID-19 and cancer
University of Liverpool
Identify vulnerable groups at risk of disease. DHSC letter of support.
University of Leicester
Risk factors of COVID-19 patients with non-alcoholic fatty liver disease
Imperial College London
Highlighting severity of COVID-19 to better inform Brazilian population
Non-organisational
Impact of COVID-19 on individuals with Down Syndrome.
Trisomy 21 Research Society
Publications (42)
Amplicon-Based Detection and Sequencing of SARS-CoV-2 in Nasopharyngeal Swabs from Patients With COVID-19 and Identification of Deletions in the Viral Genome That Encode Proteins Involved in Interferon Antagonism.
Moore SC, Penrice-Randal R, Alruwaili M, Randle N, Armstrong S, Hartley C, Haldenby S, Dong X, Alrezaihi A, Almsaud M, Bentley E, Clark J, García-Dorival I, Gilmore P, Han X, Jones B, Luu L, Sharma P, Shawli G, Sun Y, Zhao Q, Pullan ST, Carter DP, Bewley K, Dunning J, Zhou EM, Solomon T, Beadsworth M, Cruise J, Crook DW, Matthews DA, Davidson AD, Mahmood Z, Aljabr W, Druce J, Vipond R, Ng L, Renia L, Openshaw PJM, Baillie JK, Carroll MW, Stewart J, Darby A, Semple M, Turtle L, Hiscox JA.
Outcomes of Coronavirus Disease 2019 (COVID-19) Related Hospitalization Among People With Human Immunodeficiency Virus (HIV) in the ISARIC World Health Organization (WHO) Clinical Characterization Protocol (UK): A Prospective Observational Study.
Geretti AM, Stockdale AJ, Kelly SH, Cevik M, Collins S, Waters L, Villa G, Docherty A, Harrison EM, Turtle L, Openshaw PJM, Baillie JK, Sabin CA, Semple MG.
Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum.
Tuekprakhon A, Nutalai R, Dijokaite-Guraliuc A, Zhou D, Ginn HM, Selvaraj M, Liu C, Mentzer AJ, Supasa P, Duyvesteyn HME, Das R, Skelly D, Ritter TG, Amini A, Bibi S, Adele S, Johnson SA, Constantinides B, Webster H, Temperton N, Klenerman P, Barnes E, Dunachie SJ, Crook D, Pollard AJ, Lambe T, Goulder P, Paterson NG, Williams MA, Hall DR, OPTIC Consortium, ISARIC4C Consortium, Fry EE, Huo J, Mongkolsapaya J, Ren J, Stuart DI, Screaton GR.
Potent cross-reactive antibodies following Omicron breakthrough in vaccinees.
Nutalai R, Zhou D, Tuekprakhon A, Ginn HM, Supasa P, Liu C, Huo J, Mentzer AJ, Duyvesteyn HME, Dijokaite-Guraliuc A, Skelly D, Ritter TG, Amini A, Bibi S, Adele S, Johnson SA, Constantinides B, Webster H, Temperton N, Klenerman P, Barnes E, Dunachie SJ, Crook D, Pollard AJ, Lambe T, Goulder P, OPTIC consortium, ISARIC4C consortium, Paterson NG, Williams MA, Hall DR, Mongkolsapaya J, Fry EE, Dejnirattisai W, Ren J, Stuart DI, Screaton GR.
SARS-CoV-2 co-infection with influenza viruses, respiratory syncytial virus, or adenoviruses.
Swets MC, Russell CD, Harrison EM, Docherty AB, Lone N, Girvan M, Hardwick HE, ISARIC4C Investigators, Visser LG, Openshaw PJM, Groeneveld GH, Semple MG, Baillie JK.
Detection and quantification of antibody to SARS CoV 2 receptor binding domain provides enhanced sensitivity, specificity and utility.
Rosadas C, Khan M, Parker E, Marchesin F, Katsanovskaja K, Sureda-Vives M, Fernandez N, Randell P, Harvey R, Lilley A, Harris BHL, Zuhair M, Fertleman M, Ijaz S, Dicks S, Short CE, Quinlan R, Taylor GP, Hu K, McKay P, Rosa A, Roustan C, Zuckerman M, El Bouzidi K, Cooke G, Flower B, Moshe M, Elliott P, Spencer AJ, Lambe T, Gilbert SC, Kingston H, Baillie JK, Openshaw PJM, Semple MG, Cherepanov P, McClure MO, Tedder RS, ISARIC4C Investigators.